Prostate cancer survivorship and peptides — the androgen-sensitive considerations
9 min read · Uplevel editorial
The treatment worked. That's the sentence you held onto through surgery or radiation, through the PSA monitoring and the waiting, through whatever form the treatment took. And now you're on the other side of it, which is supposed to feel like a return to normal. Except your body doesn't quite feel like normal. The fatigue is different from what you expected — not the sharp tiredness of someone who didn't sleep, but a flat, low-energy baseline that seems to have settled in. The body composition has shifted in ways you didn't anticipate: muscle harder to maintain, fat redistributing in patterns you don't recognize. Sometimes the mood is off. Sometimes cognition feels less crisp. If you've been on androgen deprivation therapy, some of what you're experiencing is the documented physiological consequence of that treatment, and it is more significant than most men are told before they start.
Prostate cancer survivorship is not a single experience. It varies substantially depending on treatment type, whether androgen deprivation therapy is part of the picture, how long ADT was used, your age, your pre-treatment baseline, and a range of other individual factors. But there are threads that run through this population consistently, and they shape the context in which the growing conversation about peptides and longevity medicine has to be understood.
The first thread is testosterone. Androgen deprivation therapy works by suppressing testosterone — either through GnRH agonists or antagonists that shut down pituitary stimulation of testicular production, or through antiandrogens that block androgen receptor signaling, or through orchiectomy. The treatment is effective at its intended purpose. Its side effects are the predictable consequences of profound androgen deprivation: hot flashes, loss of muscle mass and strength, increased body fat particularly in the visceral compartment, decreased libido and erectile function, mood changes including depression, cognitive effects, fatigue, anemia, and — critically — bone density loss and cardiovascular risk elevation. These are not rare or minor. They affect a substantial portion of men on ADT and they persist for variable periods after ADT ends, sometimes for years, because the hypothalamic-pituitary-gonadal axis does not always recover quickly or completely.
The testosterone question is the most charged one in prostate cancer survivorship, and it lives in a complicated clinical space. For decades, the standard assumption was that testosterone was categorically contraindicated in prostate cancer survivors, based on the hormonal dependence of the cancer and older models of what drives recurrence. The evidence picture has become more nuanced. There is now a body of research — including trials involving testosterone replacement in carefully selected survivors with biochemical evidence of recovery and oncologic stability — suggesting that very low testosterone in survivors may carry its own risks and that cautious testosterone restoration with rigorous PSA monitoring may be appropriate for specific patients with specific cancer profiles. This is not a consensus position, and it is not an argument for reflexive testosterone supplementation in this population. It is an argument for having the conversation with your urologic oncologist. The decision belongs there, informed by your Gleason grade, treatment type, current PSA, time to treatment, and the oncologist's assessment of your individual risk profile. It does not belong in a wellness clinic that is not integrated with your oncology care.
The IGF-1 concern is closely related to the testosterone concern and maps onto the same framework. IGF-1 — insulin-like growth factor 1 — has been studied in prostate cancer biology with findings that parallel what has been found in breast cancer research: epidemiological associations between higher IGF-1 levels and prostate cancer risk, and mechanistic evidence for IGF-1's role in cancer cell survival signaling. Growth hormone secretagogues — Sermorelin, Ipamorelin, CJC-1295, MK-677, Tesamorelin — stimulate endogenous growth hormone release, which drives IGF-1 production. The appeal in a survivorship context is obvious: these compounds support muscle mass, body composition, sleep architecture, energy, and recovery — exactly the things that ADT has eroded. The concern is that IGF-1 elevation in a context where prostate cancer cells may still be present is not a mechanism to activate casually. This requires oncology coordination, direct discussion of current disease status, and a level of clinical judgment that a wellness prescriber who doesn't have your oncology record cannot provide.
HCG — human chorionic gonadotropin — is sometimes explored in men who want to restore testicular function and endogenous testosterone production after a period of suppression. In non-cancer contexts, HCG can stimulate the Leydig cells of the testes to produce testosterone when the HPG axis has been suppressed by exogenous testosterone or by GnRH analogs. In prostate cancer survivorship, the same caution applies here as with direct testosterone replacement: the stimulation of androgen production requires oncology sign-off, PSA monitoring, and a clear clinical rationale. This is not a decision to make independently.
BPC-157 and TB-500, valued in other contexts for their tissue repair and anti-inflammatory properties, carry the same proangiogenic concern in cancer survivorship that applies in other hormone-sensitive cancers. The promotion of new blood vessel formation is a healing mechanism in a recovery context. In a context where tumor recurrence is a known risk, angiogenic activity warrants careful consideration rather than assumption of safety. The research in prostate-cancer-specific contexts is limited, and limited evidence in an oncology context defaults to caution.
Growth-related peptides broadly — anything with a primary mechanism of stimulating cellular proliferation, protein synthesis, or tissue expansion — belong in the category requiring oncology discussion before use in this population.
The more appropriate territory for early consideration includes a different set of compounds, and it begins with immune support. Thymosin Alpha-1 is an immunomodulatory peptide studied in oncology contexts as an immune adjuvant — the evidence base comes primarily from Eastern European and Asian clinical research, including contexts where it has been explored in combination with conventional cancer treatments to support immune surveillance. The mechanism is immune activation and modulation rather than growth promotion. It is not an established standard of care in Western oncology, but it is also not in the same risk category as growth hormone secretagogues or anabolic compounds. The conversation with an oncologist or integrative oncologist is more likely to be genuinely exploratory than categorically closed.
Mitochondrial peptides address the energy and metabolic dimension that sits at the center of survivorship quality-of-life concerns for many men. The fatigue common during and after ADT has a mitochondrial component — estrogen deprivation in women and androgen deprivation in men both affect mitochondrial function and energy metabolism. NAD+ precursors and compounds like MOTS-c, a mitochondrial-derived peptide studied for metabolic regulation, operate at the cellular energy level without the anabolic or growth-promoting signaling that carries cancer-specific concerns. This area is still developing in terms of clinical evidence, but the mechanism is further from the concerns about androgen and IGF-1 signaling. Research is ongoing; it is not a substitute for addressing the foundational metabolic issues through diet, exercise, and sleep optimization, but it is an area where the specialist conversation is worth having.
Anti-inflammatory peptides for the post-treatment recovery period — including compounds being studied for their roles in inflammatory modulation — address a real burden in this population. Systemic inflammation is common in cancer survivors and is associated with worse outcomes across a range of metrics. Managing inflammation through the foundational approaches — nutrition, sleep, exercise, stress management — is the anchor, and where that foundation is in place, further investigational support through specialist-coordinated care may be appropriate.
The hot flash experience in prostate cancer survivors on ADT is underappreciated and undertreated. Up to eighty percent of men on ADT experience hot flashes. The mechanisms overlap with those in women during menopause — the hypothalamus losing its usual hormonal context and dysregulating thermal control. The approaches that have evidence in this population include some that have been studied in women's menopause as well: cyproterone acetate, medroxyprogesterone acetate, and low-dose antidepressants have the most clinical data. Acupuncture has been studied with positive results in some trials. This is a quality-of-life issue that is worth raising directly with your oncology team and not simply accepting as the inevitable cost of treatment.
The cardiovascular picture deserves explicit attention because it is more serious than survivorship conversations often acknowledge. ADT substantially increases cardiovascular risk: it accelerates atherosclerosis, worsens lipid profiles, increases insulin resistance, and is associated with elevated rates of metabolic syndrome. For men who already had cardiovascular risk factors before treatment, the cumulative effect can be significant. This is an argument for active cardiometabolic management — working with cardiology and primary care, not just oncology — as a formal part of survivorship care. Exercise, specifically aerobic exercise combined with resistance training, has the strongest evidence base for both the cardiovascular and the body composition effects of ADT, and it is supported in oncology survivorship guidelines. The fitness work is not optional.
Bone density follows the same imperative as in any population on long-term sex steroid suppression. ADT accelerates bone loss and increases fracture risk. DEXA scanning, calcium and vitamin D supplementation, weight-bearing exercise, and in appropriate cases bisphosphonate or denosumab therapy are the standard-of-care tools. These are not supplemental considerations — they are part of responsible survivorship management, and making sure your oncology team has addressed bone health explicitly is worth the direct conversation.
What the prostate cancer survivorship experience requires is a level of coordination across clinical domains that the conventional healthcare system is not always organized to provide efficiently. You may have a urologic oncologist managing your cancer. You may have a primary care provider managing everything else. You may or may not have an endocrinologist or cardiologist in the picture. The gap between those domains is where survivorship quality-of-life often falls, and where men sometimes find themselves exploring options that their various providers are not communicating about.
The peptide conversation, in this context, is not primarily a question of which compounds are interesting or which mechanisms are appealing. It is a question of which interventions are appropriate given your specific cancer history, your current PSA and disease status, your treatment type, your ongoing medications, and your complete clinical picture. That picture lives with your urologic oncologist, and decisions that could interact with androgen signaling, IGF-1, or growth factor pathways belong in that conversation.
This population can benefit from integrative approaches. The case for addressing fatigue, body composition, cardiovascular risk, bone density, and quality of life through the survivorship period is strong. The framework for doing it safely requires oncology partnership. The specialist who knows your cancer history is the essential starting point.
Frequently asked